Ironwood Pharmaceuticals Inc IRWD
We take great care to ensure that the data presented and summarized in this overview for IRONWOOD PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IRWD
View all-
Black Rock Inc. New York, NY22.9MShares$16.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.5MShares$14.3 Million0.0% of portfolio
-
Sarissa Capital Management LP Greenwich, CT16.4MShares$12 Million22.5% of portfolio
-
Pacer Advisors, Inc. Malvern, PA11.7MShares$8.56 Million0.13% of portfolio
-
Armistice Capital, LLC New York, NY9.47MShares$6.91 Million0.59% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny9.07MShares$6.62 Million0.06% of portfolio
-
State Street Corp Boston, MA8.33MShares$6.08 Million0.0% of portfolio
-
Braidwell LP Stamford, CT5.44MShares$3.97 Million1.35% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.69MShares$3.42 Million1.32% of portfolio
-
Lsv Asset Management Chicago, IL4.08MShares$2.98 Million0.04% of portfolio
Latest Institutional Activity in IRWD
Top Purchases
Top Sells
About IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Insider Transactions at IRWD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 02
2025
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
10,416
+5.88%
|
-
|
|
Feb 10
2025
|
Gregory S. Martini Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,052
-6.15%
|
$12,052
$1.76 P/Share
|
|
Feb 10
2025
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
38,938
-8.71%
|
$38,938
$1.76 P/Share
|
|
Feb 10
2025
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
122,222
+21.47%
|
-
|
|
Feb 10
2025
|
Michael Shetzline SVP, CMO, Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
41,269
-6.93%
|
$41,269
$1.76 P/Share
|
|
Feb 10
2025
|
Michael Shetzline SVP, CMO, Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
133,333
+18.3%
|
-
|
|
Feb 10
2025
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,048
-4.13%
|
$12,048
$1.76 P/Share
|
|
Feb 10
2025
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
139,064
-10.7%
|
$139,064
$1.76 P/Share
|
|
Jan 27
2025
|
Gregory S. Martini Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
111,111
+36.2%
|
-
|
|
Jan 27
2025
|
Ronald Silver Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
133,333
+31.37%
|
-
|
|
Jan 17
2025
|
Michael Shetzline SVP, CMO, Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
48,224
+9.45%
|
-
|
|
Jan 17
2025
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
147,354
+10.18%
|
-
|
|
Jan 17
2025
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,187
+11.01%
|
-
|
|
Dec 16
2024
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
4,249
+2.65%
|
-
|
|
Nov 18
2024
|
Sravan Kumar Emany SVP, COO and CFO |
SELL
Open market or private sale
|
Direct |
11,001
-3.43%
|
$44,004
$4.08 P/Share
|
|
Nov 18
2024
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,360
-1.85%
|
$21,440
$4.08 P/Share
|
|
Sep 16
2024
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
3,282
+2.11%
|
-
|
|
Aug 12
2024
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,910
-3.36%
|
$39,640
$4.27 P/Share
|
|
Aug 12
2024
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,107
-1.92%
|
$12,428
$4.27 P/Share
|
|
Jun 18
2024
|
Mark G Currie |
BUY
Grant, award, or other acquisition
|
Direct |
24,311
+4.1%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 951K shares |
|---|
| Open market or private sale | 499K shares |
|---|---|
| Payment of exercise price or tax liability | 18.3K shares |